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Abstract
Background: Cancer-associated fibroblasts (CAFs) are believed to play an essential role in cancer initiation and
development. However, little research has been undertaken to evaluate the role of CAFs in endometrial cancer (EC)
progression. We aim to detect the functional contributions of CAFs to promote progression of EC.
Methods: Stromal fibroblasts were isolated from endometrioid adenocarcinomas and normal endometrial tissues.
The conditioned media of cultured CAFs and normal fibroblasts (NFs) were collected to detect the level of stromal
cell-derived factor-1alpha (SDF-1α), macrophage chemoattractant protein-1 (MCP-1), migration inhibitory factor
(MIF), colony stimulating factor-1 (CSF-1), and interleukin-1 (IL-1) by ELISA. The CAFs or NFs were cocultured with EC
cell lines to determine the proliferation, migration, and invasion by MTT assays and transwell chambers. Xenograft
models were used to observe tumor growth. Matrix metalloproteinases (MMP)-2 and MMP-9 activity was evaluated
by zymography. AMD3100 (a chemokine receptor 4 (CXCR4) antagonist) was used to block the SDF-1/CXCR4 axis.
Neutralizing antibodies were used to detect PI3K/Akt and MAPK/Erk pathways by western blotting. SDF-1α and
CXCR4 expressions were analyzed in xenotransplanted tumors and 348 cases by immunohistochemistry.
Results: CAFs promoted proliferation, migration, and invasion as well as in vivo tumorigenesis of admixed EC
cells significantly more than NFs by secreting SDF-1α. These effects were significantly inhibited by AMD3100.
CAFs promoted EC progression via the SDF-1α/CXCR4 axis to activate the PI3K/Akt and MAPK/Erk signalings in a
paracrine-dependent manner or increase MMP-2 and MMP-9 secretion in an autocrine-dependent manner. SDF-1α and
CXCR4 expression upregulation accompanied clinical EC development and progression. High SDF-1α expression levels
were associated with deep myometrial invasion, lymph node metastasis, and poor prognosis in EC.
Conclusions: Our data indicated that CAFs derived from EC tissues promoted EC progression via the SDF-1/CXCR4 axis
in a paracrine- or autocrine-dependent manner. SDF-1α is a novel independent poor prognostic factor for EC patients’
survival. Targeting the SDF-1/CXCR4 axis might provide a novel therapeutic strategy for EC treatment.
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Background
Endometrial cancer (EC) is the most common gyne-
cological malignancy in developed countries, with ap-
proximately 52,630 new cases and 8590 deaths occurring
in the USA in 2014 [1]. With changes in Western lifestyles
and the rising prevalence of obesity in developing coun-
tries, the incidence of EC has increased at a surprisingly
rapid rate in China [2]. For patients with advanced or
recurrent disease or for those who wish to preserve
their fertility, the treatment options are limited. There-
fore, it is of great urgency to understand the mecha-
nisms of EC so that specific therapeutic targets can be
designed and developed.
Solid tumors, including EC, consist of tumor cells and
various types of stromal cells; thus, tumor progression is
determined not only by the tumor cells themselves but
also by the tumor stroma. Previous studies have shown
that the crosstalk between tumor cells and their sur-
rounding stroma plays an important role in tumor devel-
opment [3, 4]. Myofibroblasts in the tumor stroma,
collectively called cancer-associated fibroblasts (CAFs),
are large, spindle-shaped mesenchymal cells that share
characteristics with smooth muscle cells that expressed
both vimentin and alpha-smooth muscle actin (α-SMA)
[5]. CAFs also exhibit similar phenotypes with mesen-
chymal stem cells; both cell types secrete similar cyto-
kines [6], while mesenchymal stem cells could produce
large amounts of exosomes [7]. The presence of CAFs
was proposed to precede tumor cell initiation, prolifera-
tion, invasion metastasis, angiogenesis, and chemoresis-
tance in vitro experiments in prostate cancer, pancreatic
cancer, gastric cancer, and breast cancer [8–12]. However,
the mechanisms linking CAFs and cancer progression are
not fully understood.
CAFs can secrete variety of factors, such as cytokines,
chemokines, and growth factors. These soluble factors
are involved in paracrine signaling or in autocrine loops
to contribute to tumor progression [13], stromal cell-
derived factor-1alpha (SDF-1α) (CXCL12) is a member
of the CXC chemokine family, the chemotactic effects of
which are mediated by interaction with chemokine re-
ceptor 4 (CXCR4). Typically, SDF-1, which is expressed
in the stromal fibroblasts of some organs, including the
brain, breasts, liver, lungs, and lymph nodes, is involved
in carcinoma survival, proliferation, and metastasis
[14–16]. Malgorzata et al. found that increased expres-
sion of SDF-1 was correlated with a more aggressive
phenotype and a negative prognostic factor of EC [17].
In addition, previous studies showed that CAFs secrete
SDF-1, activate SDF-1/CXCR4 axis, and promote
tumor progression [18, 19]. Other researchers have
also showed that blocking the interaction between
SDF-1 and CXCR4 could inhibit the number or size of
tumor metastases [20–23]. Therefore, we investigated
whether CAFs played a role in promoting the progres-
sion of EC by secreting SDF-1.
To test this hypothesis, we established several primary
cultures of CAFs and normal fibroblasts (NFs) from EC
tissues and normal endometrial tissues, and then, we
cocultured CAFs or NFs with EC cell lines in vivo and
in vitro. We concluded that, in contrast to NFs, CAFs
promoted EC cell proliferation, migration, and invasion.
We measured the levels of SDF-1α in the conditioned
media harvested from NFs and CAFs. We found that
CAF-mediated EC progression was modulated via the
SDF-1/CXCR4 axis, which activated intracellular PI3K/
Akt and/or MAPK/Erk signalings and increased active
matrix metalloproteinases (MMP)-2 and MMP-9 ex-
pressions. Furthermore, we determined SDF-1α and
CXCR4 expression levels and their relationships with
clinicopathologic features and clinical outcomes in human
EC patients. This study provides new evidence elucidating
the pro-tumorigenic role of CAFs in the progression of EC.
Results
Establishment of primary fibroblast cells
To establish primary fibroblast cells, normal endometrial
tissues or EC tissues were digested with collagenase and
hyaluronidase. The primary fibroblast cells displayed elon-
gated spindle-shaped features. The fibroblast cells were
verified using anti-vimentin, anti-α-SMA, anti-fibroblast-
activating protein (FAP), and anti-fibroblast-specific pro-
tein (FSP)-1 antibodies. The antibody to CD31 was used
to demonstrate a lack of endothelial cell contamination,
while cytokeratin (CK) was used to exclude epithelial
components. CAFs isolated from EC tissues were nega-
tive for CK and CD31 expression, moderately positive
for vimentin expression, but highly positive for α-SMA,
FSP-1, and FAP expression. NFs isolated from normal
endometrial tissues showed negative expression of CK
and CD31 and moderate expression of vimentin, α-
SMA, FSP-1, and FAP. These findings are indicating
that the isolated fibroblast cells were relatively pure
and free of epithelial cells or endothelial cells contam-
ination (Fig. 1a).
CAFs promoted EC cell growth and tumorigenesis
To investigate whether CAFs play an important role in
the progression of EC, we conducted MTT assays to
evaluate the proliferation of EC cell lines cocultured with
CAFs or NFs for 4 days. Both CAFs and NFs promoted
the proliferation of HEC-1B and ECC-1 cells in a time-
dependent manner. CAFs, compared with NFs, had
more prominent potential to promote HEC-1B and
ECC-1 cell proliferation at 72 h (P < 0.05; Fig. 1b, c).
Next, to evaluate the contribution of CAFs to tumor
growth in vivo, we developed a human tumor xenograft
model that has both stromal and epithelial compartments
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in the engrafted tumors. We mixed CAFs or NFs with
HEC-1B cells at a 3:1 ratio and inoculated these mixtures
subcutaneously into the right flanks of immunodeficient
nude mice. The tumor formation was monitored. HEC-1B
cells co-mixed with CAFs generated tumors of greater
volume and weight than HEC-1B cells mixed with NFs
or HEC-1B cells alone (Fig. 2a–d). The stromal fibro-
blasts’ phenotypes were determined by immunohisto-
chemistry using antibodies specific for human CK,
vimentin, α-SMA, FAP, and FSP-1. The CAFs were nega-
tive for CK expression and weakly positive for vimentin
and α-SMA expression but moderately positive for FSP-1
and FAP expression. The NFs showed negative expression
of CK and weak expression of vimentin, α-SMA, FSP-1,
and FAP (Fig. 2e). These results suggested that the human
originated CAFs promoted the growth and tumorigenesis
of EC.
CAFs promoted EC cells migration and invasion
A coculture method was used to determine whether
CAFs secreted factors that could stimulate the migration
and invasion of EC cells in vitro. Our findings showed
that the number of migrating ECC-1 cells increased by
coculturing with CAFs, compared to coculturing with
NFs or control medium (P < 0.001; Fig. 1d). Invasion
followed the same pattern with migration; the number
of invading cells was significantly greater for coculturing
with CAFs, compared to coculturing with NFs or control
medium (P < 0.001; Fig. 1e). Consistent results were ob-
tained with HEC-1B cells (Fig. 1d, e).
Fig. 1 Identification of stromal fibroblasts and CAFs promoting EC cell proliferation, migration, and invasion. a Identification of primary cultured
fibroblast cells by immunocytochemistry (magnification ×400). b, c Cell proliferation was measured by MTT assay. d, e Crystal violet staining for
migrated and invaded EC cells (magnification ×200). Three independent experiments were performed in triplicate. Data are expressed as means ± SDs.
*P < 0.05; **P < 0.01; ***P < 0.001
Teng et al. Journal of Hematology & Oncology  (2016) 9:8 Page 3 of 15
Fig. 2 (See legend on next page.)
Teng et al. Journal of Hematology & Oncology  (2016) 9:8 Page 4 of 15
Cytokines were secreted by NFs/CAFs in the culture
supernatant
To determine the factors responsible for CAF-mediated
cell proliferation, migration, and invasion, we measured
the levels of SDF-1α, macrophage chemoattractant
protein-1 (MCP-1), migration inhibitory factor (MIF),
colony stimulating factor-1 (CSF-1), and interleukin-1
(IL-1) in the conditioned media harvested from ECC-1
cells, HEC-1B cells, NFs, and CAFs. CAFs secreted
greater amount of SDF-1α, MCP-1, and MIF when
compared to NFs and EC cells. Of this class of cyto-
kines, a significant higher level of SDF-1α than MCP-1
(approximately threefold) and MIF (approximately
threefold) levels were secreted by CAFs (Fig. 3a). There-
fore, we focused on the SDF-1α and tested the protein
concentration in the conditioned media of EC cells, NFs,
and CAFs for 24, 48, 72, and 96 h. This assay indicated
that SDF-1α in the conditioned media from CAFs was sig-
nificantly higher than that from NFs or EC cell lines
(Fig. 3b).
A crucial role for the SDF-1/CXCR4 axis in the promotion
of EC progression
Finally, to determine whether SDF-1α secreted by CAFs
was closely involved in the proliferation, migration, and
invasion of EC cells, we treated EC cells with AMD3100
(a CXCR4 antagonist) in presence of CAF-conditioned
media in vitro. SDF-1α-induced cell proliferation, migra-
tion, and invasion were significantly inhibited by AMD3100
pretreatment (Fig. 3c, e, f).
MMP-2 and MMP-9 activity was regulated by the SDF-1/
CXCR4 axis in an autocrine-dependent manner in CAFs
CAFs could dramatically increase the mobility of EC
cells and their invasion through Matrigel. These effects
of CAFs did not require direct cell-cell contact because
the conditioned media of CAFs produced essentially
the same effects. Correlated with this finding, condi-
tioned media from HEC-1B cells, NFs, and CAFs were
analyzed by zymography. Compared with conditioned
media from with NFs or HEC-1B cells, conditioned
media from CAFs resulted in increased MMP-2 and
MMP-9 gelatinase activity. When CAFs were treated
with AMD3100, MMP-2 and MMP-9 expression was
reduced (Fig. 3d). These findings indicated that CAFs
mediated the invasion and metastasis of EC via the
SDF-1/CXCR4 axis in an autocrine-dependent mode.
Activation of the PI3K/Akt and MAPK/Erk signalings in
CAF-mediated EC cells proliferation
To elucidate the mechanisms underlying the growth-
promoting effects of CAF secretion on EC, we deter-
mined the activation of PI3K/Akt and MAPK/Erk, two
major signalings implicated in EC. HEC-1B cells were
starved in serum-free medium for 12 h and incubated
with DMEM/F12, the condition media of NFs and CAFs
and CXCR4 antagonists (AMD3100 200 ng/ml, 500 ng/
ml). HEC-1B cells were pretreated with AMD3100 for
1 h and incubated with the condition media of CAFs for
30 min. Phospho-Akt and phospho-Erk 1/2 protein
levels were elevated when HEC-1B cells were treated
with CAFs supernatant compared with NFs supernatant.
Next, CXCR4 was blocked by its antagonist, and the
phosphorylation of Akt and Erk 1/2 in response to SDF-
1α was significantly decreased (Fig. 3g). In addition, we
observed that the elevated phosphorylation of Akt and
Erk 1/2 protein levels in the xenografts tumors contain-
ing CAFs compared to tumors without fibroblasts or
containing NFs (Fig. 2g). These data suggested that the
activation status of the PI3K/Akt and/or MAPK/Erk sig-
nalings might be the key point in CAF-mediated EC cells
proliferation.
Expression of SDF-1α in EC
To determine SDF-1α’s role in EC tumorigenesis and
progression, we performed immunohistochemical ana-
lysis to evaluate SDF-1α expression in xenotransplanted
tumors, as well as in normal endometrium (NE), hyper-
plastic endometrium (HE), atypical hyperplastic endo-
metrium (AHE), and EC tissue microarrays. SDF-1α
staining intensity was greater in the stromal compart-
ment than in the endometrial epithelial compartment,
and its staining was located in the membrane and/or
cytoplasm. SDF-1α expression was stronger in the xe-
nografts tumor containing CAFs compared to tumors
without fibroblasts or containing NFs (Fig. 2f ). Among
the 348 cases available for analysis, SDF-1α expression
was lowest in NE tissues; the levels were higher in HE
(See figure on previous page.)
Fig. 2 CAFs comingled with HEC-1B cells, enhancing xenograft growth in nude mice. a, b Gross appearance of xenografts; HEC-1B cells were
injected alone or were coinjected with various fibroblasts subcutaneously into the right flanks of 4-week-old nude mice, and xenografts were harvested
after 40 days of growth in female hosts. c Average tumor weight in each group was evaluated at 40 days after injection. Error bars depict the standard
error around the mean. ***P < 0.001. d Tumor volume was plotted on the indicated days. **P < 0.01; ***P < 0.001. e Sections of xenografts in different
groups were submitted to immunohistochemistry using antibodies specific for human CK, vimentin, α-SMA, FAP, and FSP-1. Scale bar, 10 μm.
f Expression of SDF-1α and CXCR4 in xenotransplanted tumors. gWestern blot analysis detection of the phosphorylation of Ark and Erk protein expression
in xenotransplanted tumors
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and AHE tissues and highest in EC tissues (χ2 = 86.826,
P = 0.000; Fig. 4a). More specifically, SDF-1α expres-
sion was significantly higher in EC tissues than in NE
tissues (P = 0.000), in HE tissues (P = 0.000), and in
AHE tissues (P = 0.000). There were significant differ-
ences in tissue SDF-1α expression between AHE and
HE tissues (P = 0.000), whereas there were no signifi-
cant differences in tissue SDF-1α expression between
AHE and NE tissues (P = 0.233) or between HE and NE
tissues (P = 0.923).
Correlations between SDF-1α expression and
clinicopathologic factors
We next analyzed the correlations between SDF-1α ex-
pression and various clinicopathologic factors that
could affect the prognosis of patients with EC. Statis-
tical analysis revealed that SDF-1α expression was
significantly increased during the NE-HE-AHE-EC se-
quence in the 348 samples. The analyses revealed that,
among the 202 EC patients, a high level of SDF-1α
expression was associated with lymph node metastasis
Fig. 3 CAFs promoted EC progression via the SDF-1α/CXCR4 axis. a Cytokines secreted by EC cells, NFs, and CAFs were measured by ELISA.
b SDF-1α protein concentration in the conditioned media was measured for 96 h by ELISA. c The effects of SDF-1α-induced proliferation of
HEC-1B cells were inhibited by AMD3100. Three independent experiments were performed in triplicate. Data are expressed as means ± SDs. *P < 0.05;
**P < 0.01; ***P < 0.001. d MMP-2 and MMP-9 gelatinase activity in the conditioned media was analyzed by zymography. e, f The effects of SDF-1α-
induced migration and invasion of EC cells were inhibited by AMD3100 (magnification ×200). g Western blot analysis detection of the phosphorylation
of Ark and Erk protein expressions in HEC-1B cells
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Fig. 4 Expression of SDF-1α and CXCR4 in EC. a SDF-1α protein expression upregulation accompanied clinical EC development and
progression. b Kaplan-Meier survival curves for overall survival according to SDF-1α staining level: negative expression, low expression, and
high expression. Overall survival was significantly different in the three groups (P = 0.039). c Kaplan-Meier survival curves for recurrence
according to SDF-1α staining level: negative expression, low expression, and high expression. Recurrent survival was significantly different
in the three groups (P = 0.032). d CXCR4 expression increased gradually in endometrial tissues as they progressed from NE to HE to AHE
and finally to EC tissues
Teng et al. Journal of Hematology & Oncology  (2016) 9:8 Page 7 of 15
(P = 0.038) and deep myometrial invasion (myometrial in-
vasion ≥1/2; P = 0.018). In contrast, SDF-1α expression
was not correlated with age at diagnosis, menopausal sta-
tus, histologic subtype, histopathologic grade, or advanced
tumor stage (Table 1).
Correlation between SDF-1α expression and survival
To investigate further the clinical relevance of SDF-1α
expression in EC, we compared overall survival accord-
ing to SDF-1α expression using Kaplan-Meier estimates.
A total of 15 patients were lost to follow-up; thus, the
data from 187 patients were included in the analysis. Of
the 32 (17.11 %) patients who died, 21 (65.62 %) died of
cancer and 11 (34.38 %) died of other causes, namely
heart failure, cerebral infarction, chronic diseases, and
cerebral hemorrhage. Remarkably, regarding the 10-year
survival rates in the negative SDF-1α expression group,
21 (95.45 %) patients survived, and 1 patient (4.55 %)
died. In the low SDF-1α expression group, 57 (87.69 %)
patients survived, and 8 patients (12.31 %) died. Finally,
in the high SDF-1α expression group, 77 (77.00 %)
patients survived, and 23 patients (23.00 %) died. These
data suggested a better prognosis for the negative SDF-
1α expression group than for the low expression and
high expression groups (χ2 = 6.473, P = 0.039; Fig. 4b).
Moreover, we also compared the correlation between
SDF-1α expression and recurrent survival. Recurrence
occurred in 23 of the 187 EC patients. In the negative
SDF-1α expression group, 1 (4.55 %) recurred. In the
low SDF-1α expression group, 4 (6.15 %) recurred. In
the high SDF-1α expression group, 18 (18.00 %) re-
curred. These data illustrated a lower trend of recur-
rence for the negative expression group than for the
low expression and high expression groups (χ2 = 6.891,
P = 0.032; Fig. 4c).
To evaluate the prognostic factors related to EC pa-
tients’ survival, hazard ratios (HRs) were estimated using
multivariate Cox regression analysis as shown in Table 2.
After adjusting for age at diagnosis, menopausal status,
tumor histopathologic grade, histopathologic subtype,
International Federation of Gynecology and Obstetrics
(FIGO) stage, and lymph node metastasis, we found that
Table 1 Associations between tissue SDF-1α expression and clinicopathologic characteristics of EC patients




Age at diagnosis (years)
<60 14 (11.2) 43 (34.4) 68 (54.4) 125 1.133 0.567
≥60 12 (15.6) 28 (36.4) 37 (48.0) 77
Menopausal status
Yes 15 (10.6) 53 (37.6) 73 (51.8) 141 2.604 0.272
No 11 (18.0) 18 (29.5) 32 (52.5) 61
Histologic subtype
Endometrioid 22 (11.9) 66 (35.7) 97 (52.4) 185 1.616 0.446
Nonendometrioid 4 (23.5) 5 (29.4) 8 (47.1) 17
Histopathologic grade
G1 14 (14.4) 34 (35.1) 49 (50.5) 97 1.460 0.834
G2 7 (9.2) 29 (38.2) 40 (52.6) 76
G3 4 (13.8) 9 (31.0) 16 (55.2) 29
Myometrial invasion
<1/2 16 (10.9) 60 (40.8) 71 (48.3) 147 7.998 0.018*
≥1/2 10 (18.2) 11 (20.0) 34 (61.8) 55
FIGO stage
I–II 22 (13.2) 63 (37.7) 82 (49.1) 167 3.456 0.172
III–IV 4 (11.4) 8 (22.9) 23 (65.7) 35
Lymph node metastasis
Yes 1 (6.3) 2 (12.5) 13 (81.2) 16 6.530 0.038*
No 24 (12.9) 70 (37.6) 92 (49.5) 186
The data are presented as numbers of cases (percentages of cases)
* indicates P < 0.05
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high expression of SDF-1α (HR, 4.13; 95 % confidence
interval (CI), 1.58–11.07; P = 0.005) and deep myome-
trial invasion (HR, 2.77; 95 % CI, 1.08–7.09; P = 0.034)
were independent factors predicting cancer-specific sur-
vival in EC patients (Table 2). Altogether, our findings
indicated that SDF-1α expression might be a useful
marker for predicting the survival of patients with EC.
Expression of CXCR4 in EC
Furthermore, we investigated CXCR4 expression in
xenotransplanted tumors, as well as in NE, HE, AHE,
and EC tissue microarrays. CXCR4 immunostaining
was more intense in the endometrial epithelium than in
the stroma, and its staining was located in the mem-
brane. CXCR4 expression was stronger in the xenograft
tumor containing CAFs compared to tumors without fi-
broblasts or containing NFs (Fig. 2f ) and increased
gradually in endometrial tissues as they progressed
from NE to HE to AHE and finally to EC tissues (χ2 =
139.485, P = 0.000; Fig. 4d). Additionally, CXCR4 ex-
pression was higher in EC tissues than in NE tissues
(P = 0.000), in HE tissues (P = 0.000) and in AHE tis-
sues (P = 0.000), whereas there were no differences be-
tween AHE and HE tissues (P = 0.111), between AHE
and NE tissues (P = 0.172), or between HE and NE tis-
sues (P = 0.443).
We also determined that CXCR4 expression in EC tis-
sues was not correlated with any prognostic factors. Fi-
nally, we found that there was no association between
CXCR4 expression in EC tissues and overall survival.
Discussion
Myofibroblast-rich cell populations, originally intro-
duced as CAFs, represent one of the most abundant
stromal cell types in various type of cancer, including
EC. Different cellular origins and tumor-derived factors
affect the phenotype of CAFs and contribute to their ap-
pearance as heterogeneous cell populations with distinct
subtypes [13]. Some studies have reported a role of pro-
moter in tumor growth and progression [24–28]; how-
ever, recent data obtained from in vitro cocultures and
in vivo xenograft models have shown a tumor-inhibitory
role of CAFs [29–32]. It remains unknown whether
CAFs in EC exhibit pro-malignant properties or anti-
malignant characteristics. To clarify this role, CAF cell
population and NF cell population were established from
human EC tissues and normal endometrial tissues. The
present study revealed that CAFs in EC were different
from the NFs in several important functional respects.
(1) CAFs were more competent than the NFs in enhan-
cing tumor growth, migration, and invasion by comin-
gling with EC cells in in vivo and in vitro experiments.
(2) CAFs produced increased level of SDF-1α and (3)
CAFs promoted EC cells progression via the SDF-1/
CXCR4 axis in a paracrine-/autocrine-dependent man-
ners. (4) SDF-1α expression was upregulated and was as-
sociated with EC progression and poor prognosis, while
the increased expression of CXCR4 in EC tissues was
not correlated with any prognostic factors.
As we know, few studies have used CAFs from human
EC samples due to the relative paucity of available fresh
tumor specimens and the limited life span of primary
Table 2 Multivariate analysis of factors associated with survival of EC patients
Variables HR 95 % CI Wald value P
Age (years) <60 1.00 0.55–3.43 0.45 0.501
≥60 1.37
Menopausal status Yes 1.00 0.18–1.90 0.83 0.363
No 0.58
Histologic subtype Endometrioid 1.00 0.67–7.82 1.74 0.187
Nonendometrioid 2.29
Histopathologic grade G1 1.00 0.55–2.97 0.31 0.578
G2–G3 1.27
Myometrial invasion <1/2 1.00 1.08–7.09 4.50 0.034*
≥1/2 2.77
FIGO stage I–II 1.00 0.43–3.99 0.22 0.639
III–IV 1.31
Lymph node metastasis Yes 1.00 0.22–2.27 0.335 0.563
No 0.71
SDF-1α expression Low expression 1.00 1.58–11.07 7.918 0.005*
High expression 4.13
*P < 0.05
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cells [33]. CAFs or NFs grow slowly and eventually sen-
esce after 10 to 15 passages; therefore, all of the primary
cells in our study were obtained at earlier than 10 pas-
sages, to maintain the closest phenotype to the primary
tissues. Our data showed that CAFs, distinctly differently
from NFs, exhibited a pro-tumorigenic effect by cocul-
ture with EC cells. Similar to Olumi’s finding [5], human
prostatic CAFs grown with initiated human prostatic
epithelial cells dramatically stimulated growth and al-
tered histology of the epithelial population. This effect
was not detected when NFs grown with initiated human
prostatic epithelial cells under identical conditions. Fur-
thermore, studies have demonstrated that stromal cells
isolated from proliferative NE are capable of suppressing
the growth of the EC cell line (Ishikawa), even in re-
sponse to estrogen [34, 35]. Such effects were specific to
the fibroblasts derived from normal endometrium be-
cause fibroblasts from normal foreskin failed to exhibit
similar effects [34]. Thus, different fibroblasts subtypes
display different phenotypes. However, it is less clear
whether fibroblast subpopulations stimulate distinct as-
pects during different stages of malignancy.
CAFs can promote tumor growth, angiogenesis, and
metastasis through communication with cancer cells,
such as by secreting various important factors in para-
crine- or autocrine-dependent manners. Among these
factors, SDF-1 has sparked substantial interest because
of its pro-tumorigenic role. SDF-1 has two major iso-
forms, α and β. Both are derived from a single gene, due
to alternative splicing. SDF-1α is the predominant iso-
form, and it is secreted by stromal cells and is found
nearly in all the organs [36]. The chemokine SDF-1 is an
important α-chemokine that binds to its cognate recep-
tor CXCR4 and regulates the trafficking of normal and
malignant cells [37]. Thus, we chose the SDF-1α as a
target in this research. We demonstrated that SDF-1α
released by CAFs induced cell proliferation, mobility, and
invasiveness in EC cells. At the same time, AMD3100, a
synthetic antagonist known to block CXCR4 function
[38], could significantly suppress these effects, consistent
with its action in other malignancies [20, 39].
Schmidt et al. have observed that SDF-1α induced the
development of EC cells in vitro [40]. However, to date,
activation of the intracellular signal transduction in-
duced by SDF-1α in EC has been seldom reported. Tsu-
kamoto and colleagues demonstrated that SDF-1α
mediated the activation of the PI3K/Akt pathway, but
not the MAPK/Erk pathway, in EC cells after treatment
with supernatants from uterine smooth muscle cells [41].
Zhao et al. reported that stimulation with exogenous SDF-
1α could induce EC cell growth through activating PI3K/
Akt and MAPK/Erk pathways in a dose-dependent man-
ner [42]. Previous studies have documented a direct in-
volvement of PI3K/Akt and Erk signaling pathways in
cardioprotection and chemotherapy resistance medi-
ated by the SDF-1/CXCR4 axis [43, 44]. Zhuo’s group
has stated that SDF-1 increased phosphorylation of Akt
and Erk1/2 in mouse lymphatic endothelial cells, when
CXCR4 was blocked by its neutralizing antibody or
knocked down by effective small interfering RNA
(siRNA) eliminated the effect of SDF-1 on activated of
Akt and Erk1/2 [45]. Similarly, these two pathways
were both activated by secretions from CAFs in our
study. In addition, AMD3100 could inhibit SDF-1α-
induced Akt and Erk activation. Our findings elucidated
that SDF-1α-induced intracellular signaling activation
was a downstream effect of CXCR4. These observations
were also compatible with changes in the biologic re-
sponses, such as cell growth, migration, and invasion,
to CAF-conditioned media treatment or to AMD3100
pretreatment of EC cells. Therefore, one potential
mechanism of CAFs promoting EC development is that
SDF-1α is engaged in tumorigenesis in a paracrine-
dependent manner.
Metastasis is an organized sequence of events begin-
ning with the detachment of neoplastic cells from a pri-
mary tumor and their entry into the circulation,
dissemination, and arrest at select organs [46]. A deg-
radation of basement membrane is the first step toward
invasion and metastasis. Type IV collagen is the main
component of basement membrane, and destruction of
this structural protein is favored by two MMPs, namely
gelatinase A (MMP-2) and gelatinase B (MMP-9) [47].
These MMPs are known to be closely associated with
the malignant potential of tumor cells. CAFs affect can-
cer cell invasion by both cell-cell contact and pro-
invasive factor secretion. CAFs are also one of the most
significant contributors to MMP production [48]. Koon-
tongkaew et al. reported that direct contact between
tumor and fibroblast cells was required to activate
MMP-2 and MMP-9 secretion in both tumor cells and
fibroblasts. Moreover, it was demonstrated that fibro-
blasts seemed to be responsible for the increased
MMP-2 in the coculture. In addition, fibroblast- or
tumor cell-conditioned media upregulated the secretion
of MMP-2 and MMP-9 in HNSCC cells. These findings
indicated that the SDF-1/CXCR4 signaling pathway
might cause an increase in cellular motility, as well as
MMP-2 and MMP-9 activation, in autocrine- and
paracrine-dependent manners [49]. However, we simply
found that the SDF-1/CXCR4 axis played a role in the
invasion and metastasis of EC in an autocrine-
dependent mode.
We investigated and clarified the clinical significance
of SDF-1α expression in EC. The data showed that SDF-
1α expression was upregulated and was associated with
tumor progression. In addition, patients with high SDF-
1α expression showed significantly poorer oncologic
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outcomes than patients with negative and low expres-
sion, suggesting that SDF-1α is an independent prognos-
tic factor in EC. In contrast, no significant associations
were documented between the expression of CXCR4
and the clinicopathologic characteristics of EC. Similarly,
this parameter was not proved to play role in the nega-
tive prognosis with this malignancy. The number of
published reports on the prognostic value of the SDF-
1/CXCR4 axis in EC patients is small [50]. Further-
more, the results of these studies have been inconclu-
sive and sometimes contradictory. Mizokami et al.
found reverse correlation between histological grade
and the stromal expression of SDF-1 and CXCR4 in 41
EC cases [51]. Another study showed that positive SDF-
1 expression was associated with longer overall survival
and longer recurrence-free survival in ER-negative pa-
tients [52]. However, in a recent study in 92 patients
with EC, the authors revealed that higher expression of
SDF-1/CXCR4 axis components was associated with
worse prognosis [17]. These evidences suggest that the
role of the SDF-1/CXCR4 axis in the progression of EC
remains undefined. It might be these studies adopted
different sets of prognostic factors and various classifi-
cation systems for protein expression.
Conclusions
Taken together, our results suggest that CAFs derived
from EC tissues promoted EC progression via the
SDF-1/CXCR4 axis. Furthermore, SDF-1α expression
emerged a novel independent poor prognostic factor
for predicting survival in patients with EC. Thus, sup-
pression of the SDF-1/CXCR4 axis in a primary tumor




This study was approved by the Ethics Committee of
Tianjin Medical University General Hospital. Written in-
formed consent was obtained from all participants.
Isolation and culture of primary fibroblast cells/cell lines
To isolate stromal fibroblasts, primary cancer tissues
were obtained from 12 EC patients at Tianjin Medical
University General Hospital (Tianjin, China). These pa-
tients had undergone hysterectomy but had not been
treated with preoperative chemotherapy or radiother-
apy. Ten NE tissues were obtained from women under-
going surgery to remove their uteruses because of
leiomyomas. The tissues were divided into two parts
for histopathological diagnosis and isolation of stromal
fibroblasts. The EC tissues used for isolation of stromal
fibroblasts were diagnosed as endometrioid adenocar-
cinomas. The fresh tissues were transported to the
laboratory in media consisting of DMEM/F12 (Gibco,
USA) supplemented with 10 % fetal bovine serum (FBS)
(Gibco, USA) and 1 % penicillin/streptomycin (Life
Technologies, USA). The tissues were minced to the
size of 1 mm3 and then were digested with collagenase
I (2 mg/ml; Sigma, USA), collagenase II (2 mg/ml;
Sigma, USA), and hyaluronidase (50 μg/ml; Sigma,
USA) in DMEM/F12, using a rotator for approximately
45 min at 37 °C. Post-digestion, the tissues were washed
and cultured in DMEM/F12 media supplemented with
10 % FBS and 1 % penicillin/streptomycin at 37 °C. The
cultures were maintained by media changes every 72 h,
and subculture was performed after the cultures
reached confluency. After two to three passages, a
unique homogeneity of stromal fibroblasts was formed.
All the stromal fibroblasts used in the experiments
were at less than 10 passages, to maintain the closest
phenotype to the primary tissues. The human EC cell
lines ECC-1 (CRL-2923) and HEC-1B (HTB 112) were
purchased from American Type Culture Collection
(Bethesda, MD, USA) and were cultured in media ac-
cording to manufacturers’ protocols.
Identification of fibroblast cells
Primary cultured fibroblasts from human EC and human
NE were also confirmed by immunocytochemistry using
rabbit anti-FSP-1 polyclonal antibody (1:300; Abcam,
UK), rabbit anti-FAP polyclonal antibody (1:500; Abcam,
UK), mouse anti-α-SMA monoclonal antibody (1:300;
Sigma, USA), rabbit anti-CK monoclonal antibody (1:500;
Abcam, UK), rabbit anti-vimentin polyclonal antibody
(1:400; Abcam, UK), and rabbit anti-CD31 polyclonal anti-
body (1:200; Abcam, United Kingdom). The cell seed sec-
tions were then treated with 0.3 % hydrogen peroxide
(H2O2) in water for 10 min to quench any endogenous
peroxidase activity within the tissue, and the nonspecific
binding sites were blocked with 0.5 % bovine serum al-
bumin for 10 min at room temperature. Next, the sec-
tions were incubated for 45 min in the presence of the
primary antibody, and then the slides were washed in
phosphate-buffered saline (PBS) containing 0.1 %
Tween 20 (PBS/Tween) for 15 min, with the solution
changed three times before the application of the sec-
ondary biotinylated antibody. The slides were incubated
with the secondary antibody for 30 min at room
temperature before being washed for 15 min in PBS/
Tween, which was changed three times. The sections
were then incubated for 15 min with an avidin-
biotinylated horseradish peroxidase complex, and the
reaction was visualized using 0.02 % 3,3′-diaminobenzi-
dine tetrahydrochloride as a chromogen in a Tris-HCl
buffer, at pH 7.6, containing 0.03 % H2O2. Hematoxylin
was used to counterstain the nuclei.
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Preparation of conditioned media
CAFs/NFs were seeded and cultured in complete media
for 24 h, before being cultured in media with serum-free
DMEM/F12 for the subsequent 72 h. Conditioned
medium was collected and centrifuged at 1000×g at 4 °C
for 15 min, and the supernatant was concentrated with
Centricon YM3 filters (Milipore). The protein in the
concentrated media was quantified using Bradford assay
(Biorad, CA, USA).
ELISA assay
CAFs or NFs were seeded on six-well plates at a density
of 1.5 × 105 cells in DMEM/F12 with 10 % FBS. After
12 h of incubation, the media was changed to 500 μl of
serum-free DMEM/F12, followed by incubation for 24,
48, and 72 h. The conditioned media was detected using
ELISA kits, according to the manufcturers’ protocol.
Coculture and cell proliferation assay
A total of 1.5 × 103 NFs or CAFs were mixed with 4.5 ×
103 HEC-1B cells or ECC-1 cells and were seeded in
complete media in 96-well plates. At 24 h post-seeding,
the cells were treated with serum-free media, AMD3100
(Sigma, USA) was added to cells at varying concentra-
tions (0, 200, 500 ng/ml). Serum-free DMEM/F12 was
added to control wells. Cell growth was analyzed at 24,
48, 72, and 96 h with the MTT reagent (Promega) added
4 h before performing spectrophotometric reading, ac-
cording to the manufacturer’s directions.
Cell migration and invasion assays
Cell invasive and migrative abilities were determined
using transwell chambers coated with or without extra-
cellular matrix gel (BD Biosciences, USA). A total of 1 ×
105 cells/well were seeded on the upper inserts with 8-
μm pores (BD Biosciences, USA) and were cultured with
serum-free media. In the lower chamber, 1 × 105 NFs or
CAFs in 500 μl of serum-free media were planted. In the
control group, there were only 500 μl of serum-free
media without fibroblasts in the lower chamber. Further-
more, various concentrations of AMD3100 were added
to the lower wells. After 24 h of incubation, the cells
on the upper surface of the filters were removed; the
filters were fixed with 4 % paraformaldehyde for
15 min and were stained with crystal violet stain for
30 min (Sigma, USA). The invasive and migrative ac-
tivity was quantified by counting the number of trans-
passed cells in five random regions (magnification,
×200) by two independent observers who were blinded
to the data. Migration and invasion assays were run in
triplicate, and the data were expressed as the average
number of cells per random area.
Nude mice xenograft assays
All of the experimental animal procedures were ap-
proved by the Animal Care and Use Committee of Tian-
jin Medical University. Four-week-old female athymic
nude mice were maintained in individually ventilated ca-
ging systems in groups of five. Established stable cells
(6 × 106 NFs or CAFs mixed with 2 × 106 HEC-1B cells)
were injected subcutaneously into the right flank of each
mouse. Tumor growth was monitored at 5-day intervals
by measuring the length and width of the tumor with
calipers and calculating the tumor volume based on the
following formula: volume = 0.5 LW2. The mice were
sacrificed, and the tumors were harvested and measured.
Western blot analysis
HEC-1B cells were seeded at 1 × 104 cells/well in six-
well plates in complete media. At 24 h post-seeding,
the cells were treated with NF-conditioned media,
CAF-conditioned media, and/or AMD3100 (200 or
500 ng/ml) for 1 h. Cell lysates or immunoprecipi-
tates from cell lysates were subjected to SDS-PAGE
and were transferred to polyvinylidene fluoride mem-
branes. The membranes were incubated with the fol-
lowing primary antibodies: rabbit anti-human Akt,
phospho-Akt, Erk, phospho-Erk, and GAPDH (Cell
Signaling Technology, USA), followed by horseradish
peroxidase-conjugated secondary antibody. The immuno-
reactive polypeptides were visualized using a chemilumin-
escent substrate (GE Life sciences).
Zymography
Conditioned media, standardized for cell numbers, were
mixed with equal volumes of nonreducing sample buffer
and were resolved on 10 % Novex Zymogram gels con-
taining 0.1 % gelatin (Sigma, USA). Renaturation and de-
tection were performed according to the manufacturer’s
instructions. Clear bands corresponding to gelatinolytic
activity were measured by densitometry.
Patients and samples
All of the cases examined in this study were obtained
from surgically removed tissues of inpatients in Tianjin
Medical University General Hospital (Tianjin, China)
from 2000 to 2012. The patients were confirmed by
histopathology, and none of them underwent radiother-
apy or chemotherapy prior to surgery. A total of 348 pa-
tients were approached. Controls were selected from
women who presented for routine examination in the
Department of Regular Physical Examination Center or
for uterine prolapse, cystocele, or urethrocele. Among
these cases, 202 patients had EC, 26 patients had HE, 33
patients had AHE, and 87 patients had NE. The histo-
logical type and grade of the primary tumors were deter-
mined by two independent pathologists based on a
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modified WHO classification system, whereas EC sta-
ging was performed based on a modified 2009 FIGO sta-
ging system.
Tissue microarray
All of the tissues for tissue microarray were obtained
from formalin-fixed, paraffin-embedded tissue blocks.
All of the cases were histopathologically re-evaluated
and their tumor content verified on hematoxylin-eosin-
stained slides. Representative areas of tumor and normal
tissue were selected to be cored. The tissue microarray
was designed and constructed using MTA Booster and
TMA Designer. The sample spots were designed to be
1.5 mm in diameter and to range in length from 2.0 to
5.0 mm, depending on the depth of tissue in the donor
block. A total of 48 such cylindrical cores were precisely
arrayed in one recipient block.
Immunohistochemistry
The streptavidin-peroxidase-biotin immunohistochemi-
cal staining method was used to study the expression of
SDF-1α and CXCR4 in tissue microarray samples.
Briefly, paraffin-embedded specimens were cut into 4-
μm sections and were baked at 60 °C for 1 h. Endogen-
ous peroxidase activity was quenched by incubation in
3 % hydrogen peroxide/methanol buffer for 30 min. The
sections were incubated in rabbit anti-SDF-1α polyclonal
antibody (1:200; Abcam, UK) or rabbit anti-CXCR4 poly-
clonal antibody (1:400; Abcam, UK) overnight at 4 °C in
humidified chambers. The following day, the sections
were washed three times in PBS and were incubated in a
peroxidase-conjugated goat anti-rabbit IgG antibody,
which came from the streptavidin-peroxidase-biotin re-
agent kit, for 30 min at 37 °C. After being washed in PBS,
the tissue sections were stained with diaminobenzidine,
counterstained with hematoxylin, and then examined
under a light microscope. As negative controls, tissue
sections were processed as described above, except
that they were incubated overnight at 4 °C in block-
ing solution with PBS.
Scoring of immunohistochemical staining
SDF-1α and CXCR4 staining was scored based on the
percentage and the intensity of positively stained cells.
The five score categories for positive staining percentage
were as follows: 0, no positive cells; 1, 25 % or fewer
positive cells; 2, 26 to 50 % positive cells; 3, 51 to 75 %
positive cells; and 4, 76 % or more positive cells. The
four score categories for staining intensity were as fol-
lows: 0, no intensity; 1, weak intensity; 2, moderate in-
tensity; and 3, strong intensity. SDF-1α and CXCR4
expression was determined by adding the positive stain-
ing percentage score to the intensity score: 0, negative
expression; ≤4, low expression; and >4, high expression.
The staining was determined independently by two pa-
thologists, who were blinded to the patients’ clinicopath-
ologic information.
Statistical analysis
Group comparisons of categorical variables were per-
formed using the χ2 test. Comparisons of average
means were performed with Student’s two-tailed t test
or one-way ANOVA. Cancer-specific survival was de-
fined from the date of surgery to the date of death from
EC. Survival curves were plotted using the Kaplan-
Meier method and were analyzed using the log-rank
test. A Cox proportional hazards model was created to
identify prognostic factors for survival. P < 0.05 was
considered to be statistically significant. All of the stat-
istical analyses were conducted using SPSS statistical
software (SPSS Inc., Chicago, IL, USA), version 14.0.
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